or Try an Advanced Search...

    Technical Analysis for JANX - Janux Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 41.66 2.57% 1.05
    JANX closed down 7.56 percent on Thursday, January 16, 2025, on 72 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical JANX trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 2.57%
    Wide Bands Range Expansion 2.57%
    Below Lower BB Weakness 2.57%
    Lower Bollinger Band Touch Weakness 2.57%
    Oversold Stochastic Weakness 2.57%
    Lower Bollinger Band Walk Weakness -5.18%
    Outside Day Range Expansion -5.18%
    Wide Bands Range Expansion -5.18%
    Gapped Up Strength -5.18%
    Below Lower BB Weakness -5.18%
    Older End-of-Day Signals for JANX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 3 hours ago
    Up 3% about 4 hours ago
    Up 2% about 4 hours ago
    Rose Above Lower Bollinger Band about 4 hours ago
    Up 1% about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    JANX Chart by TradingView

    Profile

    Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation

    Is JANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 8 Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
    Jan 3 Viking Therapeutics among potential buyout candidates: Oppenheimer
    Dec 11 Navigating 10 Analyst Ratings For Janux Therapeutics
    Dec 8 SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
    Dec 7 Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
    Dec 5 Janux Therapeutics prices $350M securities offering
    Dec 5 Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
    Dec 4 Why Janux Therapeutics Crushed the Market Today
    Dec 4 JANX Stock Hits Record High on Prostate Cancer Study Data
    Dec 3 Janux Therapeutics Announces Proposed Public Offering
    See more JANX news...

    Comments

    Indicators

    Indicator Value
    52 Week High 71.71
    52 Week Low 7.79
    Average Volume 1,185,527
    200-Day Moving Average 47.91
    50-Day Moving Average 53.62
    20-Day Moving Average 52.38
    10-Day Moving Average 49.10
    Average True Range 4.22
    RSI (14) 29.58
    ADX 14.32
    +DI 20.49
    -DI 29.88
    Chandelier Exit (Long, 3 ATRs) 51.20
    Chandelier Exit (Short, 3 ATRs) 53.02
    Upper Bollinger Bands 62.62
    Lower Bollinger Band 42.13
    Percent B (%b) -0.07
    BandWidth 39.12
    MACD Line -3.10
    MACD Signal Line -1.53
    MACD Histogram -1.5634
    Fundamentals Value
    Market Cap 1.87 Billion
    Num Shares 46.2 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -27.63
    Price-to-Sales 51.42
    Price-to-Book 1.22
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 46.25
    Resistance 3 (R3) 46.79 45.46 45.31
    Resistance 2 (R2) 45.46 44.02 45.19 45.00
    Resistance 1 (R1) 43.03 43.13 42.37 42.49 44.68
    Pivot Point 41.70 41.70 41.36 41.43 41.70
    Support 1 (S1) 39.27 40.26 38.61 38.73 36.54
    Support 2 (S2) 37.94 39.37 37.67 36.22
    Support 3 (S3) 35.51 37.94 35.91
    Support 4 (S4) 34.97